Table 1.
Baseline demographic, clinical and pathological characteristics for the overall group and the subgroups of patients with SDHD and SDHB mutation.
| Variable | All SDHx | SDHD n = 8 | SDHB n = 5 | p-value | |
|---|---|---|---|---|---|
| No. of patients, n (%) | 13 (100) | 8 (62) | 5 (38) | ||
| Mean age, years (range) | 41.9 (27–62) | 45.1 (31–62) | 36.6 (27–43) | 0.13 | |
| Gender, n (%) | |||||
| Female | 5 (38) | 4 (50) | 1 (20) | 0.42 | |
| Male | 8 (62) | 4 (50) | 4 (80) | ||
| Median time from initial diagnosis Months (range) |
48.0 (10–180) | 114.0 (10–180) | 30.0 (18–113) | 0.42 | |
| Initial performance status (PS), n (%) | |||||
| WHO/ECOG = 1 | 11 (85) | 7 (88) | 4 (80) | 0.09 | |
| WHO/ECOG = 2 | 2 (15) | 1 (12) | 1 (20) | ||
| Grading of primary tumor, n (%) | |||||
| G1 | 7 (54) | 6 (75) | 1 (25) | ||
| G2 | 6 (46) | 2 (25) | 4 (75) | ||
| Median Ki-67 index, % (95% CI) | 2.2 (1.9–6.4) | 2.0 (1.6–3.4) | 5.0 (0.8–13) | 0.048 | |
| Liver involvement n (%) | 6 (46) | 3 (38) | 3 (60) | 0.83 | |
| Presence of bone mts n (%) | 9 (41) | 4 (50) | 5 (100) | 0.86 | |
| Secretor tumors, n (%) | 4 (31) | 2 (25) | 2 (40) | 0.18 | |
| Mean initial CgA x ULN (Range) | 5.1 (0.8–26.4) | 4.7 (0.78–26.0) | 5.8 (1.4–12.0) | 0.12 | |
| SRS Krenning uptake scale 3/4 | 2/11 | 1/7 | 1/4 | 0.97 | |
The WHO/ECOG performance status (PS) grades the status of patients with respect to activities of daily living on a scale of 0 to 4, with 0 indicating that the patient is fully active. Abbreviations: mts–metastases; CgA–chromogranin A; ULN – upper limit normal.